Application, tolerance and safety of fondaparinux therapy in a German hospital: A prospective single-centre experience

Thrombosis Research

Volumn 129, Issue 1, 2012, Pages 17-21

  Schindewolf, Marc ^a   Scheuermann, Julia ^a   Kroll, Hartmut ^b   Marzi, Ingo ^a   Kaufmann, Roland ^a   Boehncke, Wolf Henning ^a   Ludwig, Ralf J ^c   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Institute for Transfusion Medicine Dessau   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Bleeding; Fondaparinux; Heparin; Heparin induced thrombocytopenia; HIT; Thrombosis

Indexed keywords

FONDAPARINUX; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DELAYED HYPERSENSITIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GERMANY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT HEMORRHAGIC PERICARDIAL EFFUSION; MEDICAL PRACTICE; MORTALITY; MUSCLE HEMATOMA; OBSERVATIONAL STUDY; PERICARDIAL EFFUSION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SCREENING; SKIN MANIFESTATION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; WELLS SCORE;

ADULT; AGED; ANTICOAGULANTS; DRUG HYPERSENSITIVITY; DRUG PRESCRIPTIONS; FEMALE; GERMANY; HEMORRHAGE; HEPARIN; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84655161994     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.06.008     Document Type: Article

References (41)

1. M. Petitou, J.C. Lormeau, and J. Choay Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs Nature 350 1991 30 33
2. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 454S 545S (Pubitemid 351892971)
3. R.A. Harrington, R.C. Becker, C.P. Cannon, D. Gutterman, A.M. Lincoff, and J.J. Popma Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 670S 707S (Pubitemid 351892975)
4. S. Baroletti, M. Labreche, M. Niles, J. Fanikos, and S.Z. Goldhaber Prescription of fondaparinux in hospitalised patients Thromb Haemost 101 2009 1091 1094
5. M. Schindewolf, J. Scheuermann, H. Kroll, J. Garbaraviciene, C. Hecking, and I. Marzi Low allergenic potential with fondaparinux: Results of a prospective investigation Mayo Clin Proc 85 2010 913 919
6. P.S. Wells, J. Hirsh, D.R. Anderson, A.W. Lensing, G. Foster, and C. Kearon Accuracy of clinical assessment of deep-vein thrombosis Lancet 345 1995 1326 1330
7. G.K. Lo, D. Juhl, T.E. Warkentin, C.S. Sigouin, P. Eichler, and A. Greinacher Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost 4 2006 759 765
8. P. Eichler, U. Budde, S. Haas, H. Kroll, R.M. Loreth, and O. Meyer First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA Thromb Haemost 81 1999 625 629 (Pubitemid 29178953)
9. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694 (Pubitemid 41647882)
10. S. Schulman, U. Angeras, D. Bergqvist, B. Eriksson, M.R. Lassen, and W. Fisher Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients J Thromb Haemost 8 2010 202 204
11. C.W. Colwell Jr., L.M. Kwong, A.G. Turpie, and B.L. Davidson Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery J Arthroplasty 21 2006 36 45 (Pubitemid 43162983)
12. R.M. Bauersachs, K. Berger, J. Hankowitz, K. Langenberg, I. Marzi, and G. Neubauer Prophylaxis, diagnosis and therapy of surgery-related complications in orthopedic and trauma surgery Eur J Trauma Emerg Surg 31 2005 158 167 (Pubitemid 40655646)
13. M. Schindewolf, B. Luxembourg, and E. Lindhoff-Last Use of fondaparinux in patients with heparin-induced thrombocytopenia type II VASA 35 2006 70
14. T.E. Warkentin, A. Greinacher, A. Koster, and A.M. Lincoff Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 340S 380S (Pubitemid 351892970)
15. M. Schindewolf, and E. Lindhoff-Last Fondaparinux-related thrombocytopenia in a patient with former HIT Response to Rota et al. (Thromb Haemost 2008; 99: 779-781). Thromb Haemost 100 2008 168 169
16. T.E. Warkentin, B.T. Maurer, and R.H. Aster Heparin-induced thrombocytopenia associated with fondaparinux N Engl J Med 356 2007 2653 2655
17. E. Rota, M. Bazzan, and G. Fantino Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT) Thromb Haemost 99 2008 779 781 (Pubitemid 351694236)
18. I. Elalamy, and B. Tribout Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal J Thromb Haemost 6 2008 1242 1243 (Pubitemid 351859140)
19. M. Schindewolf, J. Scheuermann, J. Beyer-Westendorf, S. Schellong, P. Dohmen, and J. Brachmann German Registry for use of fondaparinux in HIT or suspected HIT - preliminary data Haemostaseologie 31 2011 A10
20. T.E. Warkentin, and L.A. Linkins Non-necrotizing heparin-induced skin lesions and the 4T's score J Thromb Haemost 8 2010 1483 1485
21. B. Blakeman Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective Semin Hematol 36 1999 37 41 (Pubitemid 29045510)
22. http://www.onlinelawyersource.com/heparin/heparin-induced- thrombocytopenia.html.
23. http://www.heparinfacts.com/requestassist.htm.
24. http://www.adrugrecall.com/heparin/induced-thrombocytopenia-lawsuit.html.
25. M.A. Smythe, J.M. Koerber, M. Fitzgerald, and J.C. Mattson The financial impact of heparin-induced thrombocytopenia Chest 134 2008 568 573
26. T. Wilke, S. Tesch, A. Scholz, T. Kohlmann, and A. Greinacher The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis J Thromb Haemost 7 2009 766 773
27. A.E. Handschin, O.A. Trentz, S.P. Hoerstrup, H.J. Kock, G.A. Wanner, and O. Trentz Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro Br J Surg 92 2005 177 183 (Pubitemid 40269331)
28. A.G. Turpie, K.A. Bauer, B.I. Eriksson, and M.R. Lassen Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies Arch Intern Med 162 2002 1833 1840
29. R.J. Ludwig, M. Schindewolf, S. Alban, R. Kaufmann, E. Lindhoff-Last, and W.H. Boehncke Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides Thromb Haemost 94 2005 1265 1269 (Pubitemid 41819625)
30. M. Schindewolf, R.J. Ludwig, M. Wolter, A. Himsel, D. Zgouras, and R. Kaufmann Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin J Eur Acad Dermatol Venereol 22 2008 378 380 (Pubitemid 351247440)
31. R.J. Ludwig, C. Beier, E. Lindhoff-Last, R. Kaufmann, and W.H. Boehncke Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans Contact Dermatitis 49 2003 158 159 (Pubitemid 38021667)
32. U. Jappe, U. Juschka, N. Kuner, B.M. Hausen, and K. Krohn Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases Contact Dermatitis 51 2004 67 72 (Pubitemid 39331598)
33. G.T. Gerotziafas, and M.M. Samama Heterogeneity of synthetic factor Xa inhibitors Curr Pharm Des 11 2005 3855 3876 (Pubitemid 41632242)
34. A.S. Dunn, A.C. Spyropoulos, and A.G. Turpie Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT) J Thromb Haemost 5 2007 2211 2218 (Pubitemid 47617873)
35. G. Agnelli, D. Bergqvist, A.T. Cohen, A.S. Gallus, and M. Gent Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery Br J Surg 92 2005 1212 1220 (Pubitemid 41475229)
36. F.F. van Doormaal, G.E. Raskob, B.L. Davidson, H. Decousus, A. Gallus, and A.W. Lensing Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials Thromb Haemost 101 2009 762 769
37. R.J. Ludwig, S. Alban, R. Bistrian, W.H. Boehncke, R. Kaufmann, and R. Henschler The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo Thromb Haemost 95 2006 535 540
38. M. Altinbas, H.S. Coskun, O. Er, M. Ozkan, B. Eser, and A. Unal A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 2004 1266 1271 (Pubitemid 40186120)
39. A.Y. Lee, F.R. Rickles, J.A. Julian, M. Gent, R.I. Baker, and C. Bowden Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism J Clin Oncol 23 2005 2123 2129 (Pubitemid 46218703)
40. N. Hostettler, A. Naggi, G. Torri, R. Ishai-Michaeli, B. Casu, and I. Vlodavsky P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins FASEB J 21 2007 3562 3572 (Pubitemid 350075146)
41. J.L. Stevenson, S.H. Choi, and A. Varki Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity Clin Cancer Res 11 2005 7003 7011 (Pubitemid 41428760)